Fig. 6

Comparison of myeloid malignancies after exclusion of cell type-specific CpGs. a, b Multidimensional scaling plots of DNAm profiles (216,532 CpG sites) in patients with PMF, MDS, JMML, AML, and healthy controls (peripheral blood (PB) and bone marrow (BM)): a) first versus second dimension; b) third versus fourth dimension. c Scatter plots showing mean DNAm beta values of healthy control versus PMF, MDS, JMML, or AML, accounting for potential differences between peripheral blood and bone marrow by using appropriate control sets. Significant hypo- and hypermethylated CpGs are indicated in blue and red (mean DNAm difference > 20%; adjusted p-values < 0.05). Gray numbers indicate all CpGs exceeding the mean DNAm difference > 20%, irrespective of statistical significance. d, e Venn diagrams illustrating CpGs that are overlapping d) hyper- or e) hypomethylated in the above-mentioned comparisons of four myeloid malignancies after the exclusion of cell type-specific CpGs